Madison Vaccines Receives $8,000,000 Series A Funding

  • Feed Type
  • Date
    1/14/2014
  • Company Name
    Madison Vaccines
  • Mailing Address
    505 South Rosa Road Madison, WI 53719
  • Company Description
    The principal mission of Madison, Wisconsin-based MVI is the development of therapeutic plasmid DNA vaccine products for patients with prostate cancer. MVI is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines.
  • Website
    http://www.madisonvaccines.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $8,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The proceeds will support ongoing development of MVI’s pipeline, including completion of an expanded Phase 2 clinical trial for MVI-816 in non-metastatic prostate cancer patients with rapidly rising PSA, before the need for surgical or chemical castration (androgen deprivation therapy or ADT).
  • M&A Terms
  • Venture Investor
    Venture Investors
  • Venture Investor
    WARF
  • Venture Investor
    Venture Management
  • Venture Investor
    State of Wisconsin Investment Board

Trending on Xconomy